180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Up 77.1% in October

180 Life Sciences Corp. (NASDAQ:ATNF) saw a large increase in short interest in October. As of October 31st, there was short interest totalling 139,400 shares, an increase of 77.1% from the October 15th total of 78,700 shares. Approximately 28.5% of the company’s stock are short sold. Based on an average daily volume of 1,950,000 shares, the short-interest ratio is currently 0.1 days.

180 Life Sciences Stock Performance

Shares of 180 Life Sciences stock traded down $0.18 on Friday, hitting $2.50. 79,378 shares of the company’s stock traded hands, compared to its average volume of 798,758. 180 Life Sciences has a 52-week low of $1.16 and a 52-week high of $17.75. The firm’s 50-day moving average is $2.65 and its 200 day moving average is $2.14.

180 Life Sciences (NASDAQ:ATNF) last posted its quarterly earnings results on Monday, August 12th. The company reported $0.01 earnings per share (EPS) for the quarter.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.